Work

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9047

Authors: Martin Reck, Tom Karagiannis, Thomas Wehler, Mikhail Shtivelband, Jose-Luis Gonzalez-Larriba, Jeffrey Rothenstein, Martin Frueh, Yu Deng, Ariel Lopez-Chavez, Alan Sandler, Mark A. Socinski

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Genentech, Universitätsklinikum des Saarlandes, Hospital Clínico San Carlos, Lakeridge Health, Kantonsspital St. Gallen, Florida Hospital Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892356278

Cites:

Cited by: 14

Related to: 10